CYP21A2

Steroid 21-hydroxylase · P08686 · CYP21A2 on Sugi Atlas →

11,390 patent compounds predicted against CYP21A2, 8,153 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Levoketoconazole (SCHEMBL8407)	1.00	16/20
Ketoconazole (SCHEMBL8408)	1.00	16/20
Levoketoconazole (SCHEMBL41473)	1.00	16/20
Levoketoconazole (SCHEMBL1517472)	1.00	16/20
Levoketoconazole (SCHEMBL3144078)	0.99	16/20
Levoketoconazole (SCHEMBL1065525)	0.92	16/20
Levoketoconazole (SCHEMBL459801)	0.88	16/20
Levoketoconazole (SCHEMBL959168)	0.88	16/20
SCHEMBL2615047	0.86	16/20
Levoketoconazole (SCHEMBL2857633)	0.81	16/20
Levoketoconazole (SCHEMBL1217855)	0.79	16/20
Levoketoconazole (SCHEMBL1923552)	0.79	16/20
SCHEMBL2615046	0.76	16/20
SCHEMBL2615048	0.76	16/20
Levoketoconazole (SCHEMBL2414969)	0.70	16/20
SCHEMBL1152682	0.64	16/20
Levoketoconazole (SCHEMBL3134999)	0.63	16/20
Levoketoconazole (SCHEMBL1462596)	0.61	16/20
SCHEMBL1152193	0.57	16/20
SCHEMBL1153076	0.57	16/20

Clinical trials — most relevant to CYP21A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency	PHASE4	UNKNOWN
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment	PHASE4	RECRUITING
Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia	PHASE3	COMPLETED
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy	PHASE3	WITHDRAWN
Androgen Reduction in Congenital Adrenal Hyperplasia	PHASE2	WITHDRAWN
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia	PHASE2	COMPLETED
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia	PHASE1/PHASE2	COMPLETED
AMG 386 and Abiraterone for Advanced Prostate Cancer	PHASE2	COMPLETED
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer	PHASE2	RECRUITING
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia	PHASE2	COMPLETED
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma	PHASE2	UNKNOWN
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia	PHASE2	COMPLETED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia	PHASE2	COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency	PHASE1	COMPLETED
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Linear Growth of Children With Congenital Adrenal Hyperplasia	nan	UNKNOWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers	nan	UNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency	nan	COMPLETED
Final Height in Patients With CAH	nan	UNKNOWN
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.	nan	UNKNOWN
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH	nan	COMPLETED
Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty	nan	UNKNOWN
rhGH Therapy on Hepatic Drug Metabolism	nan	COMPLETED
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
Testicular Adrenal Rest Tumor in Congenital Adrenal Hyperplasia Patients Attending Assuit University Children Hospital	nan	NOT_YET_RECRUITING
Hydrocortisone Modified-release in Adults: Real-world Monitoring of Longitudinal Outcomes in coNgenital Adrenal hYperplasia	nan	NOT_YET_RECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Gene Polymorphisms Influencing Steroid Synthesis and Action	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CYP21A2 binder may also engage these)

Protein	Name	Similarity
Q8WNW0	—	1.000	Q8WNW0 →
P03940	—	1.000	P03940 →
P00191	—	0.999	P00191 →
Q64562	—	0.998	Q64562 →
Q2LA60	—	0.996	Q2LA60 →
P15540	—	0.996	P15540 →
P12394	—	0.995	P12394 →
Q2LA59	—	0.993	Q2LA59 →
Q2LCM1	—	0.993	Q2LCM1 →
Q9QUJ1	—	0.985	Q9QUJ1 →
P30437	—	0.985	P30437 →
Q64680	—	0.983	Q64680 →
O35084	—	0.983	O35084 →
P70085	—	0.983	P70085 →
CYP4F3	Cytochrome P450 4F3	0.982	landscape →
P10633	—	0.982	P10633 →
P24456	—	0.981	P24456 →
Q9QYG5	—	0.981	Q9QYG5 →
Q29473	—	0.981	Q29473 →
Q6A152	—	0.980	Q6A152 →
Q64403	—	0.980	Q64403 →
Q29488	—	0.980	Q29488 →
CYP2R1	Vitamin D 25-hydroxylase (EC 1.14.14.24) (Cyt	0.979	landscape →
E9Q816	—	0.977	E9Q816 →
P11714	—	0.977	P11714 →
Q6VVW9	—	0.976	Q6VVW9 →
Q01361	—	0.976	Q01361 →
CYP4Z1	Cytochrome P450 4Z1	0.976	landscape →
CYP8B1	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase	0.976	landscape →
A0A087X1C5	—	0.975	A0A087X1C5 →